Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22992536 | 0.69 | CYP1A2 (0.36) | MIFL3MBTL1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL22992364 | 0.68 | CYP1A2 (0.48) | CYP1A2 | |
| SCHEMBL14402121 | 0.67 | PPARD (0.44) | — | |
| SCHEMBL11836856 | 0.66 | CYP1A2 (0.46) | L3MBTL1CYP1A2MEN1KMT2AALDH1A1 | |
| SCHEMBL31674096 | 0.65 | L3MBTL1 (0.48) | L3MBTL1 | |
| SCHEMBL11622190 | 0.63 | CYP1A2 (0.38) | MIFUSP2HTTCYP1A2KMT2A | |
| SCHEMBL24776233 | 0.63 | L3MBTL1 (0.41) | MIFL3MBTL1CYP1A2MEN1KMT2A | |
| SCHEMBL22992504 | 0.62 | POLB (0.52) | L3MBTL1USP2CYP1A2MEN1KMT2A | |
| SCHEMBL22992502 | 0.62 | POLB (0.52) | L3MBTL1USP2CYP1A2MEN1KMT2A | |
| SCHEMBL9979486 | 0.61 | FFAR1 (0.47) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | MIF 18/4885L3MBTL1 4577/4885USP2 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.